A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-004656-30

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

1.To evaluate the comparative bioavailability of the MK-1439 100 mg adult formulation tablets under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated and coated granules, 0.8 mg per granule [100 mg total dose], under fasting conditions 2.To evaluate the comparative bioavailability of the MK- 1439 100 mg investigational oral pediatric uncoated granule formulation, 0.8 mg per granule [100 mg total dose], under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated granules, 0.8 mg per granule [100 mg total dose], under fasting conditions, when given with vanilla pudding or applesauce 3.To evaluate the comparative bioavailability of the MK- 1439 100 mg investigational oral pediatric coated granules, 0.8 mg per granule [100 mg total dose], under fasting conditions to MK-1439 100 mg investigational oral pediatric coated granules, 0.8 mg per granule [100 mg total dose], under fasting conditions when given with vanilla pudding or applesauce


Critère d'inclusion

  • HIV-1 infection

Liens